| OCLG Stock | | | USD 0.0001 0.00 0.00% |
CFO
Mr. Michael A. Kramarz, CPA serves as Chairman of the Board, Chief Executive Officer, Chief Financial Officer of the Company. Mr. Kramarz was first employed by the Company in September 2002, as its Controller. Mr. Kramarz is responsible for all financial statement, accounting and tax functions. From 1995 to 2002, Mr. Kramarz was employed as Accounting Manager for Assurant Group, where he was responsible for the accounting and payroll functions for two inbound call centers. In addition, Mr. Kramarz was responsible for quarterly consolidations into the parent company. From 1992 to 1995, Mr. Kramarz was a staff accountant at VandenToorn Associates CPA firm where his was responsible for compilations and reviews of financial statements, as well as tax return preparation. Mr. Kramarz holds a Certified Management Accountant Designation and a Certified Public Accountant Designation since 2016.
| Age | 53 |
| Tenure | 8 years |
| Phone | 616-977-9933 |
| Web | https://www.oclghealth.com |
Kramarz holds a BS and Business Administration in Accounting from Aquinas College and a Masters in the Science of Taxation from Grand Valley State University.
Oncologix Tech Management Efficiency
The company has return on total asset
(ROA) of
(0.1183) % which means that it has lost $0.1183 on every $100 spent on assets. This is way below average. Oncologix Tech's management efficiency ratios could be used to measure how well Oncologix Tech manages its routine affairs as well as how well it operates its assets and liabilities.
Oncologix Tech currently holds 3.97
M in liabilities. Oncologix Tech has a current ratio of 0.27, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Oncologix Tech until it has trouble settling it off, either with new capital or with free cash flow. So, Oncologix Tech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oncologix Tech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oncologix to invest in growth at high rates of return. When we think about Oncologix Tech's use of debt, we should always consider it together with cash and equity.
Similar Executives
Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. Oncologix Tech, Inc. was founded in 1995 and is based in Lafayette, Louisiana. Oncologix Tech operates under Shell Companies classification in the United States and is traded on OTC Exchange. It employs 191 people. Oncologix Tech [OCLG] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Oncologix Tech Leadership Team
Elected by the shareholders, the Oncologix Tech's board of directors comprises two types of representatives: Oncologix Tech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncologix. The board's role is to monitor Oncologix Tech's management team and ensure that shareholders' interests are well served. Oncologix Tech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncologix Tech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Oncologix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Oncologix Tech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Oncologix Pink Sheet
Oncologix Tech financial ratios help investors to determine whether Oncologix Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncologix with respect to the benefits of owning Oncologix Tech security.